It is well known that up to 40% of human prostate cancers show loss of at least one copy of the PTEN gene via submicroscopic deletion [27-29] and that the percent of tumors harboring PTEN deletions increases with disease progression and in advanced castration resistant disease [19,20]. This evidence concerns the gene PTEN and prostate cancer.